(Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Verma earned her medical degree at Maharishi Dayanand University in Rohtak, India, completed her internal medicine training at Civil hospital, Ballabgarh, India, and served as a staff physician active in clinical research in Faridabad, India. in Molecular Biology and completed a post-doctoral fellowship at the University of California Irvine, during which she performed and published on important research in breast cancer biology and targets for therapeutic intervention in breast cancer.
BRIDGE DIAGNOSTICS INC PDF FULL
As VP, Genomic Services she led the development and implementation of numerous molecular diagnostic assays using the full spectrum of cutting edge molecular biologic techniques and technologies. a leading contract diagnostics organization (CDO) for the biopharmaceutical and diagnostic industries and long-time CLIA laboratory partner of Lucid Diagnostics. Prior to that, over the previous decade, she served in various research scientist and senior executive roles at Irvine, CA-based ResearchDx, Inc. Verma most recently served as VP, Research & Development at Irvine, CA-based Bridge Diagnostics, a National Molecular Laboratory focused on infectious disease and women’s health. “I look forward to working with my Lucid colleagues, as well as our industry and academic partners to advance the underlying science of our assay, continually improve its performance, and expand our portfolio of molecular diagnostic tools in esophageal disease and beyond.”ĭr. “I am excited to join this remarkable company and team, and I look forward to contributing to Lucid’s important mission of preventing deadly esophageal cancer,” said Dr. We are so fortunate to have someone with such deep experience and expertise in cutting-edge molecular diagnostics techniques and technology, as well as intimate knowledge of all aspects of the EsoGuard assay, to serve as our Chief Scientific Officer.” Verma played a central role in transferring the EsoGuard ® Esophageal DNA Test from the Case Western Reserve University research laboratory to a commercial laboratory setting, completing the CLIA validation process, and launching EsoGuard as a commercially available Laboratory Developed Test. “In her role as VP of Genomic Services at our CLIA laboratory partner, ResearchDx, Dr. Verma to the Lucid Diagnostics team,” said Lishan Aklog M.D., Lucid’s Chairman and Chief Executive Officer. Suman Verma appointed Chief Scientific Officer of Lucid Diagnostics (Photo: Business Wire)
0 kommentar(er)
